Previous 10 | Next 10 |
2024-02-08 11:37:46 ET More on Agios Pharmaceuticals, AIM ImmunoTech, etc. CVS Health Corporation (CVS) Q4 2023 Earnings Call Transcript CVS Health FY23 Earnings: Downgrades Inevitable, Long Term Outlook In The Balance CVS Health Corporation 2023 Q4 - Results - Earni...
Efficacy results offer preliminary evidence that Ampligen may reduce fatigue in subjects with Post-COVID conditions Safety results show Ampligen is generally well tolerated in the treatment of Post-COVID Conditions OCALA, Fla., Feb. 08, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoT...
OCALA, Fla., Jan. 24, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has received authorization from the Erasmus Medical Center (“Erasmus MC”) Ethics Committee to open a Europ...
OCALA, Fla., Jan. 22, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the first subject has been enrolled at Erasmus Medical Center (“Erasmus MC”) in a Phase 1b/2 clinical trial c...
First enrollment and first subject dosing expected soon at Erasmus Medical Center in Rotterdam, Netherlands Management discusses the announcement and what this means here: video OCALA, Fla., Jan. 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AI...
AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that shareholders have elected all four of the Company’s directors, Stewart L. Appelrouth, Nancy K. Bryan, Thomas K. Equels and William M. Mitchell, at the Company’s 2023 An...
Kellner Seeking Expedited Appeal of Delaware Court Finding that Nomination Notice was Properly Denied PR Newswire Court Found that Several AIM Advance Notice Bylaws Are Invalid NEW YORK , Jan. 3, 2024 /PRNewswire/ -- Ted D. Kellner, Todd Deutsc...
Court Finds Activist Group “Flouted” AIM’s Bylaws by Failing to Provide Required Information AIM Will Reconvene Annual Meeting Today and then Adjourn Until January 5 th Any Proxies Submitted by Activist Group Will Be Disregarded AIM Urges Sharehold...
AIM Will Convene Annual Meeting on December 1 st and then Adjourn Until December 29 th to Give Delaware Court Additional Time to Deliver Ruling in Activist Group Litigation AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announ...
Extends certain exclusive U.S. rights to Ampligen for cancer and ME/CFS through 2039 Management discusses patent issuance and what this means in a brief video: here OCALA, Fla., Nov. 27, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM...
News, Short Squeeze, Breakout and More Instantly...
AIM ImmunoTech Inc. Company Name:
AIM Stock Symbol:
NYSE Market:
Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications Compa...
Continued execution across Ampligen ® clinical development programs and growing body of positive data in multiple high-value indications Company to host conference call and webcast today, May 16, at 8:30 AM ET OCALA, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech...
OCALA, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") announced today that management will host...